

HEAR LIFE TO THE FULLEST

SECOND QUARTER 2021 EARNINGS CALL AUGUST 12, 2021

CONFERENCE CALL LOGISTICS

Available Documents • Release, accompanying slides and replay web cast are available online at ir.eargo.com • Supplemental historical financial information provided on slides 11 and 12 Digital Conference Call Replay • ir.eargo.com

TODAYS SPEAKERS

Christian Gormsen, President and Chief Executive Officer

Adam Laponis, Chief Financial Officer

Nick Laudico, Vice President, Investor Relations


FORWARD-LOOKING STATEMENTS

This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact contained in this presentation are forward-looking statements, including statements regarding our full year 2021 financial guidance, our ability to deliver on that guidance while driving innovation, the acquisition of assets from Clementine further advancing our long-term strategic initiative, and third-party payor audit. Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that could cause actual results and events to differ materially from those anticipated, including, but not limited to, risks, uncertainties and assumptions related to: the outcome of ongoing third-party payor audits and the risk that insurance companies may seek recoupments of previous claims paid and deny any claims subject to the audits, and we have received some denials to date, or future claims if the audits are not concluded in our favor following processes for appeal and, if necessary, corrective action; the risk that we may not meet our financial guidance, which assumes favorable conclusion of the ongoing audit being conducted by our largest third-party payor; the impact of unfavorable resolutions of third-party payor audits on our future financial results, including our revenue recognition, sales return rate and bad debt reserve; our expectations concerning additional orders by existing customers; our expectations regarding the potential market size and size of the potential consumer populations for our products and any future products, including our ability to maintain or increase insurance coverage of Eargo hearing aids; our ability to release new hearing aids and the anticipated features of any such hearing aids; developments and projections relating to our competitors and our industry, including competing products; our ability to maintain our competitive technological advantages against new entrants in our industry; the pricing of our hearing aids; our expectations regarding the ability to make certain claims related to the performance of our hearing aids relative to competitive products; our expectations with regard to changes in the regulatory landscape for hearing aid devices, including the implementation of the pending over-the-counter hearing aid pathway regulatory framework; and our estimates regarding the COVID-19 pandemic, including but not limited to, its duration and its impact on our business and results of operations. These and other risks are described in greater detail under the section titled "Risk Factors" contained in Eargo's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q and the company's other filings with the SEC. Any forward-looking statements in this presentation are made pursuant to the Private Securities Litigation Reform Act of 1995, as amended, are based on current expectations, forecasts and assumptions, and speak only as of the date of this presentation. Except as required by law, the company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

Use of Non-GAAP Financial Measures

The company may report non-GAAP results for gross profit/loss, gross margin, operating expenses, operating margins, net income/loss, and basic and diluted net income/loss per share in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. The company's financial measures under GAAP include charges such as stock-based compensation, as listed in the itemized reconciliations between GAAP and non-GAAP financial measures included in this presentation. Management has excluded the effects of this item in non-GAAP measures to assist investors in analyzing and assessing past and future operating performance. Reconciliations of non-GAAP measures disclosed in this presentation appear below. The company encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand its business.

2Q21 FINANCIAL PERFORMANCE



2Q21 Accomplishments

- √ 44% year-over-year revenue growth
- ✓ Initial launch of Eargo 5
- ✓ Acquisition of Clementine hearing screening technology



Our most revolutionary product ever

- ✓ Launched on schedule: Initial shipments late 2Q21; full commercial launch early 3Q21
- ✓ Robust media campaign
- ✓ Strong initial commercial traction
- ✓ List price \$2,950
 - Significant capabilities upgrade with no list price increase to Eargo NEO HiFi

Eargo 5 is the ultimate Eargo device, allowing the user to customize their device to their hearing needs. Plus, incredibly rich and clear audio, all within our smallest device ever.

EARGO 5, TUNED TO YOU. BY YOU

EARGO Acquisition of Clementine

- Completed the acquisition of Clementine during 2Q21 for total purchase price of \$2.9M
- Developer of web-based hearing screen technology currently used on Eargo web site as well as kiosk
- Strategic tool to access more consumers across wide range of digitally an in-person settings
- Focused on technology optimization and FDA registration in 2022 prior to commercial testing
- ► Expect acquisition to have no impact to FY21 revenues and modestly increase FY21 R&D expenses

SET UP What kind of listening device are you using?







Set Up Progress

NEXT >

Web Screener



Kiosk

COMPARISON OF 2Q21 AND 2Q20 RESULTS

(all \$ in millions)

(an ϕ in initiality)	2Q '20	2Q '21	
Net Revenue	\$15.9	\$22.9	
YoY % Growth	122.5%	43.7%	
Gross Systems Shipped	9,040	12,548	Strong performance of digital and national advertising, increased insurance market penetration
% Growth	82.4%	38.8%	•
Return Accrual Rate	27.1%	24.1%	Strong mix of insurance customers
Non-GAAP Gross Margin	67.3%	72.3%	Higher customer ASP, lower return rate, lower COGS per unit
Non-GAAP S&M	\$10.7	\$20.0	
% of Net Rev	67.2%	87.4%	Expanded investments in demand generation, Eargo 5 launch preparations
Non-GAAP R&D	\$2.1	\$4.1	
% of Net Rev	13.3%	17.7%	
Non-GAAP G&A	\$3.0	\$6.3	
% of Net Rev	18.9%	27.5%	
Non-GAAP Total Operating Expenses	\$15.8	\$30.4	
Non-GAAP Operating Loss	(\$5.1)	(\$13.8)	

2021 FINANCIAL OUTLOOK

- Increasing full year net revenue guidance from between \$89 million and \$93 million to between \$93 million and \$96 million
- Reiterating GAAP gross margin guidance of between 68% and 71%
- Reiterating non-GAAP gross margin of between 70% and 72%



GAAP TO NON-GAAP RECONCILIATION

(all \$ in 000's)

	Q1'19A	Q2'19A	Q3'19A	Q4'19A	Q1'20A	Q2'20A	Q3'20A	Q4'20A	Q1'21A	Q2'21A
Gross Systems Shipped	5,363	4,955	5,257	7,212	7,030	9,040	10,077	12,096	11,704	12,548
Unit Growth Rate YoY					31.1%	82.4%	91.7%	67.7%	66.5%	38.8%
Total Return Rate	(37%)	(34%)	(35%)	(34%)	(28%)	(27%)	(25%)	(24%)	(23%)	(24%)
Net Revenue	\$7,290	\$7,155	\$7,730	\$10,615	\$12,669	\$15,921	\$18,186	\$22,378	\$22,048	\$22,883
YoY Growth					73.8%	122.5%	135.3%	110.8%	74.0%	43.7%
QoQ Growth		(1.8%)	8.0%	37.3%	19.4%	25.7%	14.2%	23.1%	(1.5%)	3.8%
GAAP Gross Profit	\$3,467	\$3,528	\$4,147	\$5,858	\$8,013	\$10,716	\$12,751	\$15,800	\$15,751	\$16,421
% Gross Margin	47.6%	49.3%	53.6%	55.2%	63.2%	67.3%	70.1%	70.6%	71.4%	71.8%
SBC expense	\$1	\$3	<u>\$3</u>	<u>\$9</u>	<u>\$5</u>	<u>\$4</u>	<u>\$9</u>	<u>\$43</u>	<u>\$186</u>	\$113
Non-GAAP Gross Profit	\$3,467	\$3,531	\$4,150	\$5,867	\$8,018	\$10,720	\$12,761	\$15,843	\$15,937	\$16,534
% Non-GAAP Gross Margin	47.6%	49.4%	53.7%	55.3%	63.2%	67.3%	70.2%	70.8%	72.2%	72.3%

Totals may not tie to financial statements due to rounding

GAAP TO NON-GAAP RECONCILIATION (CONTINUED)

(all \$ in 000's)

	Q1'19A	Q2'19A	Q3'19A	Q4'19A	Q1'20A	Q2'20A	Q3'20A	Q4'20A	Q1'21A	Q2'21A
GAAP S&M	\$7,663	\$7,745	\$9,290	\$11,027	\$10,859	\$10,828	\$12,354	\$15,484	\$16,855	\$21,903
% of Net Rev	105.1%	108.2%	120.2%	103.9%	85.7%	68.0%	67.9%	69.2%	76.4%	95.7%
SBC expense	<u>(\$7)</u>	<u>(\$46)</u>	<u>(\$73)</u>	<u>(\$62)</u>	<u>(\$123)</u>	(\$126)	<u>(\$344)</u>	<u>(\$1,035)</u>	<u>(\$1,856)</u>	<u>(\$1,899)</u>
Non-GAAP S&M	\$7,656	\$7,698	\$9,217	\$10,965	\$10,736	\$10,702	\$12,009	\$14,449	\$14,999	\$20,004
% of Net Rev	105.0%	107.6%	119.2%	103.3%	84.7%	67.2%	66.0%	64.6%	68.0%	87.4%
GAAP R&D	\$2,669	\$2,893	\$3,219	\$4,060	\$2,809	\$2,208	\$2,871	\$4,157	\$4,778	\$5,148
% of Net Rev	36.6%	40.4%	41.6%	38.2%	22.2%	13.9%	15.8%	18.6%	21.7%	22.5%
SBC expense	<u>(\$16)</u>	(\$84)	(\$83)	(\$49)	<u>(\$164)</u>	(\$91)	<u>(\$295)</u>	(\$272)	(\$1,067)	(\$1,100)
Non-GAAP R&D	\$2,654	\$2,809	\$3,136	\$4,011	\$2,645	\$2,118	\$2,577	\$3,885	\$3,711	\$4,048
% of Net Rev	36.4%	39.3%	40.6%	37.8%	20.9%	13.3%	14.2%	17.4%	16.8%	17.7%
GAAP G&A	\$2,421	\$2,677	\$3,683	\$3,689	\$6,078	\$3,257	\$5,163	\$6,084	\$7,487	\$8,432
% of Net Rev	33.2%	37.4%	47.6%	34.8%	48.0%	20.5%	28.4%	27.2%	34.0%	36.8%
SBC expense	<u>(\$84)</u>	<u>(\$300)</u>	<u>(\$298)</u>	<u>(\$222)</u>	<u>(\$233)</u>	<u>(\$250)</u>	<u>(\$719)</u>	<u>(\$1,376)</u>	(\$2,022)	(\$2,129)
Non-GAAP G&A	\$2,337	\$2,378	\$3,385	\$3,467	\$5,845	\$3,006	\$4,444	\$4,708	\$5,465	\$6,303
% of Net Rev	32.1%	33.2%	43.8%	32.7%	46.1%	18.9%	24.4%	21.0%	24.8%	27.5%
GAAP Total Operating Expenses	\$12,753	\$13,315	\$16,192	\$18,776	\$19,746	\$16,293	\$20,388	\$25,725	\$29,120	\$35,483
% of Net Rev	174.9%	186.1%	209.5%	176.9%	155.9%	102.3%	112.1%	115.0%	132.1%	155.1%
SBC expense	<u>(\$106)</u>	(\$430)	<u>(\$454)</u>	<u>(\$333)</u>	<u>(\$520)</u>	<u>(\$467)</u>	(\$1,358)	(\$2,683)	(\$4,945)	(\$5,128)
Non-GAAP Total Operating Expenses	\$12,647	\$12 ,885	\$15,738	\$1 8,443	\$19,226	\$15,826	\$19,030	\$23,042	\$24,175	\$30,355
% of Net Rev	173.5%	180.1%	203.6%	173.7%	151.8%	99.4%	104.6%	103.0%	109.6%	132.7%
GAAP Loss from Operations	(\$9,286)	(\$9,787)	(\$12,045)	(\$12,918)	(\$11,733)	(\$5,577)	(\$7,637)	(\$9,925)	(\$13,369)	(\$19,062)
Stock-based compensation	<u>\$107</u>	<u>\$433</u>	<u>\$457</u>	<u>\$342</u>	<u>\$525</u>	\$471	\$1,367	\$2,726	\$5,131	\$5,241
Non-GAAP Loss from Operations	(\$9,180)	(\$9,354)	(\$11,588)	(\$12,576)	(\$11,208)	(\$5,106)	(\$6,269)	(\$7,199)	(\$8,238)	(\$13,821)
OI&E	\$63	\$28	(\$112)	(\$429)	(\$5)	(\$1,015)	(\$2,090)	(\$1,874)	(\$252)	(\$260)
GAAP Net loss and comprehensive loss	(\$9,223)	(\$9,759)	(\$12,157)	(\$13,347)	(\$11,738)	(\$6,592)	(\$9,726)	(\$11,799)	(\$13,621)	(\$19,322)
Stock-based compensation	<u>\$107</u>	<u>\$433</u>	<u>\$457</u>	\$342	<u>\$525</u>	<u>\$471</u>	\$1,367	\$2,726	\$5,131	\$5,241
Non-GAAP Net loss and comprehensive loss	(\$9,116)	(\$9,326)	(\$11,700)	(\$13,005)	(\$11,214)	(\$6,121)	(\$8,359)	(\$9,073)	(\$8,490)	(\$14,081)
COGS	\$1	\$3	\$3	\$9	\$5	\$4	\$9	\$43	\$186	\$113
S&M	\$7	\$46	\$73	\$62	\$123	\$126	\$344	\$1,035	\$1,856	\$1,899
R&D	\$16	\$84	\$83	\$49	\$164	\$91	\$295	\$272	\$1,067	\$1,100
G&A	\$84	\$300	\$298	\$222	\$233	\$250	\$719	\$1,376	\$2,022	\$2,129
Total stock-based compensation	\$107	\$433	\$457	\$342	\$525	\$471	\$1,367	\$2,726	\$5,131	\$5,241

Totals may not tie to financial statements due to rounding

12

GAAP TO NON-GAAP GROSS MARGIN GUIDANCE RECONCILIATION

Reconciliation Between GAAP and non-GAAP Full Year 2021 Forecasted Gross Margin

	Low	High
GAAP Gross Margin	68%	71%
Stock-based Compensation Expense	2.0%	1.0%
Non-GAAP Gross Margin	70%	72 %

THANK YOU